Free Trial

Aptose Biosciences (APTO) Competitors

$1.13
+0.02 (+1.80%)
(As of 05/28/2024 ET)

APTO vs. TIL, PASG, AVRO, CVM, CRIS, IKNA, TSBX, GNTA, CRTX, and TARA

Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Instil Bio (TIL), Passage Bio (PASG), AVROBIO (AVRO), CEL-SCI (CVM), Curis (CRIS), Ikena Oncology (IKNA), Turnstone Biologics (TSBX), Genenta Science (GNTA), Cortexyme (CRTX), and Protara Therapeutics (TARA). These companies are all part of the "medical" sector.

Aptose Biosciences vs.

Aptose Biosciences (NASDAQ:APTO) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Aptose Biosciences currently has a consensus target price of $17.50, suggesting a potential upside of 1,448.67%. Instil Bio has a consensus target price of $25.00, suggesting a potential upside of 128.10%. Given Aptose Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Aptose Biosciences is more favorable than Instil Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptose Biosciences
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Instil Bio
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Aptose Biosciences has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Instil Bio has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.

Aptose Biosciences received 282 more outperform votes than Instil Bio when rated by MarketBeat users. Likewise, 65.73% of users gave Aptose Biosciences an outperform vote while only 52.51% of users gave Instil Bio an outperform vote.

CompanyUnderperformOutperform
Aptose BiosciencesOutperform Votes
376
65.73%
Underperform Votes
196
34.27%
Instil BioOutperform Votes
94
52.51%
Underperform Votes
85
47.49%

In the previous week, Aptose Biosciences and Aptose Biosciences both had 4 articles in the media. Instil Bio's average media sentiment score of 1.25 beat Aptose Biosciences' score of 0.94 indicating that Instil Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aptose Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Instil Bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

26.6% of Aptose Biosciences shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 4.6% of Aptose Biosciences shares are held by insiders. Comparatively, 46.5% of Instil Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Instil Bio's return on equity of -51.27% beat Aptose Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptose BiosciencesN/A -1,003.74% -257.64%
Instil Bio N/A -51.27%-35.73%

Instil Bio is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/A-$51.21M-$6.20-0.18
Instil BioN/AN/A-$156.09M-$18.93-0.58

Summary

Aptose Biosciences beats Instil Bio on 9 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APTO vs. The Competition

MetricAptose BiosciencesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$18.41M$2.87B$5.00B$8.09B
Dividend YieldN/A2.24%2.74%3.96%
P/E Ratio-0.1828.61176.4818.43
Price / SalesN/A305.672,386.6172.31
Price / CashN/A162.8533.0728.77
Price / Book-5.954.124.944.39
Net Income-$51.21M-$45.89M$104.35M$213.55M
7 Day Performance-1.74%-3.27%-0.63%-0.80%
1 Month Performance-7.38%4.60%3.85%3.42%
1 Year Performance-82.06%2.83%5.47%7.53%

Aptose Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TIL
Instil Bio
3.0977 of 5 stars
$11.04
-1.8%
$25.00
+126.4%
-11.6%$71.76MN/A-0.5849Short Interest ↑
Positive News
Gap Down
PASG
Passage Bio
2.4665 of 5 stars
$1.13
-7.4%
$9.00
+696.5%
+17.2%$69.65MN/A-0.7458Gap Down
High Trading Volume
AVRO
AVROBIO
2.9599 of 5 stars
$1.51
+7.1%
$2.00
+32.5%
+26.3%$67.78MN/A0.0013Short Interest ↑
High Trading Volume
CVM
CEL-SCI
0 of 5 stars
$1.23
-3.1%
N/AN/A$66.62MN/A-1.95N/A
CRIS
Curis
2.2743 of 5 stars
$11.20
+0.5%
$37.33
+233.3%
-34.3%$65.97M$10.02M-1.3049Positive News
Gap Up
IKNA
Ikena Oncology
2.6792 of 5 stars
$1.33
+3.9%
$9.50
+614.3%
-77.7%$64.18M$3.85M-0.8434Short Interest ↓
News Coverage
TSBX
Turnstone Biologics
2.6808 of 5 stars
$2.60
+0.8%
$19.00
+630.8%
N/A$60.14M$19.31M-0.2682Gap Up
GNTA
Genenta Science
2.9243 of 5 stars
$3.30
+8.9%
$25.00
+657.6%
-43.5%$60.13MN/A0.0014Short Interest ↓
News Coverage
Positive News
Gap Up
CRTX
Cortexyme
0 of 5 stars
$1.95
+2.6%
N/A-41.8%$58.79MN/A-0.6655
TARA
Protara Therapeutics
1.9258 of 5 stars
$2.80
+1.4%
$26.50
+846.4%
-5.4%$57.65MN/A-0.7526Short Interest ↑

Related Companies and Tools

This page (NASDAQ:APTO) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners